Contrast-Enhanced Ultrasound with Lumason/Definity as a Screening Tool for Kidney Cancer in Patients with Von Hippel-Lindau

Inclusion Criteria

• Able to provide written informed consent
• Willing to comply with protocol requirements
• Carry a diagnosis of VHL, Birt-Hogg-Dube syndrome (BHD), hereditary leiomyomatosis and renal cell carcinoma (HLRCC), or tuberous sclerosis complex (TSC) and able to undergo routine clinical screening tests for renal cell carcinoma (RCC)

Exclusion Criteria

• Critically ill or medically unstable or in an intensive care setting and whose critical course during the observation period would be unpredictable
• Known hypersensitivity to sulfur hexafluoride or to any component of perflutren lipid (Definity) or sulfur hexafluoride (Lumason)
• Right to left shunt, severe pulmonary hypertension (pulmonary artery pressure > 90 mmHg), or adult respiratory distress syndrome
• Active cardiac disease including any of the following: * Severe congestive heart failure (class IV in accordance with the classification of the New York Heart Association) * Unstable angina * Symptomatic arrhythmia (i.e. tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation, ventricular tachycardia, atrial flutter or fibrillation) * Myocardial infarction within 14 days prior to the date of proposed microbubble administration
• Has any other medical condition or other circumstances that would significantly decrease the chances of obtaining reliable data or of achieving the study objectives such as: * Mental illness * Drug abuse
• Female patient who is pregnant or lactating
• Obesity that limits obtainment of acceptable images